| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/23/2011 | CA2782601A1 Novel antiplatelet agent |
| 06/23/2011 | CA2782574A1 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment |
| 06/23/2011 | CA2782555A1 3-(indolyl)-or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma |
| 06/23/2011 | CA2782524A1 3'-deoxy-3'-methylidene-.beta.-l-nucleosides |
| 06/23/2011 | CA2782472A1 Method of treating scars and beta-catenin-mediated disorders |
| 06/23/2011 | CA2782464A1 New ccr2 receptor antagonists and uses thereof |
| 06/23/2011 | CA2782453A1 N-linked hydroxamic acid derivatives useful as antibacterial agents |
| 06/23/2011 | CA2782361A1 Bridgehead amine ring-fused indoles and indolines useful to treat neurodegenerative and neuropsychiatric disorders |
| 06/23/2011 | CA2782236A1 Treatment composition and method |
| 06/23/2011 | CA2782213A1 1,7-diazacarbazoles and their use in the treatment of cancer |
| 06/23/2011 | CA2782172A1 Azaindole glucokinase activators |
| 06/23/2011 | CA2781999A1 Parenteral pharmaceutical formulation in suspension, having sustained release, in low and ultralow dosage, in hormonal therapy in the climacteric syndrome |
| 06/23/2011 | CA2781495A1 Pyrrolidine derivatives |
| 06/23/2011 | CA2781390A1 Bridged bicyclic rho kinase inhibitor compounds, composition and use |
| 06/23/2011 | CA2781199A1 Suppository comprising pantoprazole |
| 06/23/2011 | CA2781186A1 New phenylhydrazone derivatives and their use as pharmaceuticals |
| 06/23/2011 | CA2781112A1 Use of alpha 2 adrenergic receptor agonists for treating or preventing psoriasis |
| 06/23/2011 | CA2780876A1 Chalcones as enhancer of antimicrobial agents |
| 06/23/2011 | CA2780526A1 Heterocyclic antiviral compounds |
| 06/23/2011 | CA2780290A1 Mk2 inhibitors |
| 06/23/2011 | CA2780155A1 Ethynyl derivatives |
| 06/23/2011 | CA2780006A1 Tricyclic antibiotics |
| 06/23/2011 | CA2771188A1 Passive solid tumor-targeted pectin-doxorubicin prodrug and preparation method thereof |
| 06/22/2011 | EP2336322A1 Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production |
| 06/22/2011 | EP2336321A1 Ox2 receptor homolog |
| 06/22/2011 | EP2336320A1 Sensizitation of cancer cells to therapy using sina targeting genes from the 1p and 19q chromosomal regions |
| 06/22/2011 | EP2336317A1 Double-stranded ribonucleic acid with increased effectiveness in an organism |
| 06/22/2011 | EP2336303A1 NKT CELL-DERIVED iPS CELLS AND NKT CELLS DERIVED THEREFROM |
| 06/22/2011 | EP2336281A1 Use of anionic isosorbide derivatives (III) |
| 06/22/2011 | EP2336184A2 Administration of agents for the treatment of inflammation |
| 06/22/2011 | EP2336166A1 Compositions that inhibit proliferation of cancer cells |
| 06/22/2011 | EP2336151A1 Replikin peptides and uses thereof |
| 06/22/2011 | EP2336150A2 Replikin peptides and uses thereof |
| 06/22/2011 | EP2336146A1 17beta-hydroxysteroid dehydrogenase inhibitors |
| 06/22/2011 | EP2336145A1 Antisense modulation of apolipoprotein B expression |
| 06/22/2011 | EP2336144A1 Esterified alpha-galactosylceramide |
| 06/22/2011 | EP2336141A2 Phosphoramidate alkylator prodrugs |
| 06/22/2011 | EP2336140A2 Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents |
| 06/22/2011 | EP2336139A2 Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents |
| 06/22/2011 | EP2336138A2 Prodrugs of HIV protease inhibitors |
| 06/22/2011 | EP2336136A1 Pyridine derivatives and their use in the treatment of psychotic disorders |
| 06/22/2011 | EP2336135A2 1-[2',3'-dideoxy-3'c-(hydroxymethyl)- beta-d-erythro-pentofuranosyl]cytosine derivatives as HIV inhibitors |
| 06/22/2011 | EP2336134A1 Fitness assay and methods for reducing resistance of HIV to therapy |
| 06/22/2011 | EP2336133A1 Purine analogs having HSP90-inhibiting activity |
| 06/22/2011 | EP2336132A1 Morpholinopurine derivative |
| 06/22/2011 | EP2336131A1 Hydantoin compounds |
| 06/22/2011 | EP2336129A1 1-aza-bicyclo[3.3.1]nonanes |
| 06/22/2011 | EP2336128A1 Benzoisothiazoles and preparation and uses thereof |
| 06/22/2011 | EP2336127A1 Tiotropium salts, method for creating same and medicinal formulations containing same |
| 06/22/2011 | EP2336126A1 Tiotropium salts, method for their production and medicinal formulas containing them |
| 06/22/2011 | EP2336124A1 Stable hydrate of a muscarinic receptor antagonist |
| 06/22/2011 | EP2336123A2 Heterocyclic compound as protein kinase inhibitor |
| 06/22/2011 | EP2336122A1 1-pyrimidinyl- or 1-pyridinyl-2-amino benzimidazole derivatives and related compounds as inhibitors of protein kinases for the treatment of cancer |
| 06/22/2011 | EP2336120A1 Combinations containing amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors |
| 06/22/2011 | EP2336117A1 Heterocyclic compounds for treating retinal diseases |
| 06/22/2011 | EP2336115A1 Dihydropyrimidine compounds and use thereof for the treatment of viral diseases |
| 06/22/2011 | EP2336113A1 CRTH2 Receptor Ligands for Medical Use |
| 06/22/2011 | EP2336111A1 Heterocyclic inhibitors of p38 |
| 06/22/2011 | EP2336109A1 Novel pyrrolinone derivative and medicinal composition containing same |
| 06/22/2011 | EP2336108A1 Hybrid tripyrrole-octaarginine compounds and their use as medicament in the treatment of cancer and microbial illnesses |
| 06/22/2011 | EP2336107A2 Proton pump inhibitors |
| 06/22/2011 | EP2336105A1 Nitrogen-containing heterocyclic compound and use of same |
| 06/22/2011 | EP2336103A2 HCL-polymorphs of 3-[2-(Dimethylamino)methyl-(cyclohex-1-yl)]phenol |
| 06/22/2011 | EP2335779A1 Small Molecule Inhibitors of Retroviral Assembly & Maturation |
| 06/22/2011 | EP2335734A2 Treatment of pain and other alpha 2 adrenergic-mediated conditions |
| 06/22/2011 | EP2335733A1 Specific therapy using integrin ligands for treating cancer |
| 06/22/2011 | EP2335717A1 PAR-1 antagonists for use in the treatment or prevention of influenza virus type a infections |
| 06/22/2011 | EP2335711A2 Extract of hancornia speciosa and pharmaceutical composition thereof |
| 06/22/2011 | EP2335709A1 Insulin resistance improving agent |
| 06/22/2011 | EP2335708A1 Sulphated glycosaminoglycans, including heparin and derivatives thereof, for use in inhibiting the expression of hepcidin and for the therapeutic treatment of anaemia with high levels of hepcidin |
| 06/22/2011 | EP2335707A1 Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| 06/22/2011 | EP2335706A1 Preparation of thioarabinofuranosyl compounds and use thereof |
| 06/22/2011 | EP2335705A1 Use of sphingomyelin for the treatment of influenza |
| 06/22/2011 | EP2335704A1 Pharmaceutical composition comprising a strontium salt, vitamine D and a cyclodextrine |
| 06/22/2011 | EP2335703A1 Compositions and Methods for Preventing or Reducing Postoperative Ileus and Gastric Stasis in Mammals |
| 06/22/2011 | EP2335702A1 Product containing at least one phosphatase Cdc25 inhibitor combined with at least one other anticancer agent |
| 06/22/2011 | EP2335701A1 Heterocyclic aspartyl protease inhibitors |
| 06/22/2011 | EP2335700A1 Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| 06/22/2011 | EP2335699A1 Synergistic combination of analgesic compounds |
| 06/22/2011 | EP2335698A1 Pharmaceutical solid preparation having active ingredients separated by boundary therein |
| 06/22/2011 | EP2335697A1 Stable pharmaceutical formulation with limited discoloration |
| 06/22/2011 | EP2335696A1 An entacapone-containing oral dosage form |
| 06/22/2011 | EP2335695A1 Use of aminapthone for the preparation of a medicament for treating arteriophaties |
| 06/22/2011 | EP2335694A1 Thyroid hormone analogs and methods of use. |
| 06/22/2011 | EP2335693A2 Therapeutic use of nitric oxide precursor |
| 06/22/2011 | EP2335692A1 Silicone liquid and fluorinated liquid for sequential use in the treatment of retinal tears and/or detachments |
| 06/22/2011 | EP2335691A1 Formulations comprising vardenafil with controlled release of active ingredient |
| 06/22/2011 | EP2335690A1 Mucoadhesive buccal tablets for the treatment of orofacial herpes |
| 06/22/2011 | EP2335688A1 Pharmaceutical compositions comprising sigma receptor ligands |
| 06/22/2011 | EP2335686A1 An aqueous intravenous nanosuspension with reduced adverse effects |
| 06/22/2011 | EP2335495A1 Carnitine granulate and methods for its production |
| 06/22/2011 | EP2334826A2 Method of detection and diagnosis of oral and nasopharyngeal cancers |
| 06/22/2011 | EP2334823A1 Methods and compositions for diagnosing and treating a colorectal adenocarcinoma |
| 06/22/2011 | EP2334793A1 Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene |
| 06/22/2011 | EP2334791A1 Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl trna synthetase |
| 06/22/2011 | EP2334789A1 Breast cancer related gene rqcd1 |
| 06/22/2011 | EP2334786A2 Isolation and identification of glycosaminoglycans |
| 06/22/2011 | EP2334706A1 Identification of a conserved inner core oligosaccharide region of moraxella catarrhalis lipopolysaccharide as a vaccine antigen |
| 06/22/2011 | EP2334689A2 Fused heterocyclic compound |
| 06/22/2011 | EP2334687A1 Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives |